Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05788666

Use of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease

This study seeks to expand the use of the NYU GeriKit mobile application ("app") in a diverse range of settings to better phenotype older patients, which will enhance both research and patient care.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ischemic Heart Disease Cardiovascular Diseases Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

75 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NYU Langone Health

New York, 10016, United States

Location status: Recruiting

Location contact

John Dodson, MD

PRINCIPAL_INVESTIGATOR

About this study

This is a single-center proof of concept study of geriatric impairments and feasibility metrics through the use of the GeriKit software application in older adults with ischemic heart disease at the NYU Langone Medical Center. The GeriKit mobile application was developed to make geriatric assessment instruments easily accessible to clinicians who do not have subspecialty training in geriatrics. The GeriKit app has been used clinically but is untested in research settings.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 75
  • Currently hospitalized for acute mycardial infarction (AMI), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG); or hospitalized for AMI, PCI, or CABG within the prior 4 weeks
  • Capable of self-consent
  • Understand and are able to perform study procedures in English

Exclusion criteria

  • Non-ambulatory
  • Moderate or severe cognitive impairment (operationalized as known diagnosis of dementia)
  • Unable or unwilling to consent
  • Incarcerated
  • Unable to use complete assessments in English
  • Unable to complete geriatric assessment for other reasons

Treatment and study plan

GeriKit Mobile Application

Procedure

Digital health app used for comprehensive geriatric assessment (CGA). The app includes a series of brief, well-validated instruments: the MiniCog, 30-Second Chair Stand, Activities of Daily Living, Instrumental Activities of Daily Living, Patient Health Questionnaire (PHQ-9), Mini Nutrition Assessment, 2-Item Fall Screen, and Polypharmacy screen.

Primary outcomes

  1. Incidence of Mortality or Hospital Readmission

    Time frame: Month 6

    Binary outcome; determined by review of patient electronic health record (EHR) data at Month 6.

Secondary outcomes

  1. 12-Item Short Form Survey (SF-12) Score

    Time frame: Baseline

    The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality-of-life measure. SF-12 consists of 12 questions that are scored in various ways. The total score range is 12-48; the higher the score, the higher the score, the better the physical and mental health functioning.

  2. 12-Item Short Form Survey (SF-12) Score

    Time frame: Month 6

    The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality-of-life measure. SF-12 consists of 12 questions that are scored in various ways. The total score range is 12-48; the higher the score, the higher the score, the better the physical and mental health functioning.

  3. Seattle Angina Questionnaire Short-Form (SAQ-7)

    Time frame: Baseline

    7-item questionnaire assessing functional status, angina and disease-specific health-related quality of life (HRQoL) over a four-week recall period. Responses generate a summary score ranging from 0-100, where 100 = full health, and 0 = worst health.

  4. Seattle Angina Questionnaire Short-Form (SAQ-7)

    Time frame: Month 6

    7-item questionnaire assessing functional status, angina and disease-specific health-related quality of life (HRQoL) over a four-week recall period. Responses generate a summary score ranging from 0-100, where 100 = full health, and 0 = worst health.

Study contacts

Contact information is provided by the study sponsor or research team.

John A. Dodson, MD, MPH, FACC

CONTACT

[email protected]

(646) 501-2714

Victoria Rosado Santiago

CONTACT

[email protected]

9(917) 838-1699

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Collaborators

  • National Institutes of Health (NIH)

Registry information

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Mar 29, 2023
Registry last updated
Dec 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.